[Intravitreal injection of bevacizumab (Avastin) for retinal angiomatous proliferation].
METHODS
An 81-year-old man presented with stage 2 retinal angiomatous proliferation (RAP) as identified by fluorescein angiography and optical coherence tomography (OCT), and was shown to have a visual acuity (VA) of 20/40. One week after an intravitreal injection of bevacizumab (1.25 mg) the VA improved to 20/25, and the OCT showed a reduction of both intraretinal edema and pigment epithelium detachment. Three months after the injection, no ocular complications were observed, VA was 20/20 and the OCT showed an almost normal macular contour.


CONCLUSIONS
Intravitreal injection of bevacizumab may provide another treatment option for patients with RAP.
Amselem
L
L
Consorcio Hospital General Universitario de Valencia, Valencia, España. luisamselem@yahoo.es
Díaz-Llopis
M
M
Cervera
E
E
García-Delpech
S
S
Moratal-Peiro
B
B
Palomares
P
P
D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000473:pathology; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab